Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
13 août 2024 06h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
09 août 2024 07h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
08 août 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
02 juil. 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
18 juin 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
30 mai 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
28 mai 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 16h10 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
26 mars 2024 06h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
21 mars 2024 07h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum